MDs on Botox Utility (MOBILITY)

Allergan

Status: Completed

Conditions: Strabismus; Blepharospasm; Muscle Spasticity; Torticollis

Treatments: Other: botulinum toxin type A

Study type: Observational

Funder types: Industry

Identifiers

NCT00535938

AGN/MMC B00705

Details and patient eligibility

About

The MOBILITY Project is a prospective, non-randomized, observational, multi-centre evaluation of Health Utility via the SF-12® Health Survey Scores and the SF-6D in patients receiving BOTOX® for therapeutic use.

Enrollment: 1,372 patients

Sex: All

Ages: 14+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are eligible for BOTOX® treatment deemed medically necessary by their physician
• Patient (and/or patient's authorized legal representative) should provide written informed consent; a patient under the age of 18 must review and sign the Patient Assent Form
• Patients at the age of or over 14

Exclusion criteria

• Patient is participating in a clinical trial for any BOTOX® indication
• Patient with any contraindications to use botulinum toxin A

Trial design

1,372 participants in 2 patient groups

Naïve to Botox® treatment

Description:

Initiating treatment with BOTOX® upon entry to the project.

Treatment:

Other: botulinum toxin type A

Non-naïve to Botox® treatment

Description:

Receiving ongoing treatment with BOTOX® upon entry to the project.

Treatment:

Other: botulinum toxin type A